Immunohistochemistry showed that BYSL immunoreactivity was located in both the cytoplasm and nuclei (Figure 1G) and that the percentage of BYSL-IR cells was significantly increased in grade III (P < 0.001) and grade IV (P < 0.001) glioma tissues (Figure 1H). This evidence concerns the gene BYSL and central nervous system cancer.